Spongistatin 1 is a new experimental chemotherapeutic agent isolated from marine sponges. Here we show that spongistatin 1 potently induces cell death in patient primary acute leukemic cells with higher efficiency than 8/10 clinically used cytotoxic drugs and prevents long-term survival of leukemic cell lines. Spongistatin 1 triggers caspase-dependent apoptosis in Jurkat T cells by the release of cytochrome c, Smac/DIABLO and Omi/ HtrA2. As caspase-9 acts as an initiator caspase and Bcl-2 and Bcl-xL overexpression suppress spongistatin 1-induced apoptosis, cell death is mediated through the mitochondrial apoptosis pathway. Importantly, spongistatin 1 leads to the degradation of the antiapoptotic X-linked inhibitor of apoptosis protein. In apoptosis-resistant leukemic tumor cells overexpressing XIAP, spongistatin 1 effectively causes cell death and potentiates cell death induction by other apoptosis-promoting factors that might be caused by spongistatin 1-mediated degradation of XIAP. Our data show that spongistatin 1 represents a promising novel therapeutic agent for the treatment of leukemic tumor cells especially in the clinically highly relevant situation of chemoresistance due to overexpression of XIAP.
Introduction
Spongistatin 1 is a macrocyclic lactone that has been isolated from the marine sponges Spirastrella spinispirulifera and Hyrtios erecta. 1 In the 60 cell line in vitro screen of the National Cancer Institute spongistatin 1 has been shown to potently kill several solid tumor cell lines, including melanoma, lung and colon cancer cells. Even though the spongistatins are structurally complex, the total synthesis of spongistatin 1 has been just accomplished. 2 Recently, spongistatin 1 was shown to have an apoptosis-inducing effect in A549 cells by activating caspase-3 and by the cleavage of vimentin. 3 However, virtually no work has been carried out to elucidate the activity and underlying mechanisms of spongistatin 1 in leukemia. Acute leukemia is an aggressive hematologic malignancy and the identification of more effective drugs remains a high priority for leukemia research. The current primary treatment for acute leukemia is chemotherapy, which induces apoptosis. Two major apoptotic pathways are described to be utilized by cytotoxic drugs. The first, referred to as the extrinsic pathway, is triggered through the ligation of a death receptor and the assembly of the death-inducing signaling complex (DISC), followed by the release of the activated caspase-8 from the DISC. 4 The second, intrinsic pathway is activated by anticancer drugs or growthfactor deprivation and involves activation of mitochondria.
A bevy of proapoptotic and antiapoptotic proteins regulates the balance between cell growth and cell death. Alterations in these particular pathways are important in drug resistance. Indeed, resistance to chemotherapy was found to be related to increased levels of the mitochondria-protecting proteins Bcl-2 and Bcl-xL. 5, 6 Besides these, inhibitor of apoptosis proteins (IAPs) are shown to be overexpressed in cancer cell lines and in primary tumor biopsy samples, and are associated with resistance to apoptosis. 5, [7] [8] [9] In addition to these expression studies, direct genetic evidence is emerging that IAPs can function as oncogenes. 10, 11 Drugs designed to specifically target these antiapoptotic proteins might be valuable to overcome chemoresistance. Proof-of-concept data using antisense strategy and peptide inhibitors suggest an important role for these proteins in promoting resistance to apoptosis induction by anticancer drugs. [12] [13] [14] Here we show that spongistatin 1 induces apoptosis in Jurkat leukemia T cells and, more importantly, in primary leukemia cells. Spongistatin 1 triggers cell death by the intrinsic pathway using caspase-9 as initiator caspase. Notably, spongistatin 1 has the ability to induce XIAP protein degradation and cell death in XIAP-overexpressing Jurkat cells and therefore targets an important molecular key in the apoptosis resistance of cancer cells. Moreover, spongistatin 1 enhances cell death induced by staurosporine. As the combination of these two substances is even more effective in XIAP-overexpressing cells, spongistatin 1 may provide a beneficial strategy in the combat of chemoresistance caused by overexpression of this protein.
Materials and methods

Compounds
Spongistatin 1 has been isolated from the sponges Spirastrella spinispirulifera and Hyrtios erecta.
1 Before application, spongistatin 1 was dissolved and further diluted in dimethyl sulfoxide (DMSO). Final DMSO concentration did not exceed 1%, a concentration verified not to interfere with the experiments performed. Staurosporine and the caspase inhibitor zVAD-fmk were purchased from Merck Biosciences (Darmstadt, Germany). Methotrexate, was obtained from Calbiochem (San Diego, CA, USA), 4-hydroperoxy-cyclophosphamide from Baxter oncology GmbH (Frankfurt, Germany), all further reagents were obtained from Sigma (Deisenhofen, Germany).
Cell culture
Human leukemia Jurkat T cells (S-Jurkat, clone J16), the CD95-deficient R-Jurkat, 15 Fas-associated death domain (FADD)-deficient A3, 16 Jurkat transfected with vector control (Neo), Bcl-xL or Bcl-2, 17 Jurkat T cells (clone A3) and caspase-8 deficient A3, 18 caspase-9 deficient Jurkat 19 and X-Jurkat stably overexpressing XIAP 20 were cultured (37 1C and 5% CO 2 ) in RPMI 1640 containing 2 mM L-glutamine (PAN Biotech, Aidenbach, Germany) supplemented with 10% fetal calf serum (FCS) gold (PAA Laboratories, Cö lbe, Germany) and 1% pyruvate (Sigma Deisenhofen, Germany). Medium of transfected cells was supplemented with 1 mg/ml G418 (PAA Laboratories GmbH, Linz, Austria) every fifth passage. Primary leukemic blasts were obtained from children treated for acute leukemia at the Ludwig Maximilians University's childrens' hospitals in 2006/2007. Samples were obtained by bone marrow puncture at initial diagnosis or diagnosis of relapse and isolated using Ficoll Isopaque (Amersham Pharmacia Biotech, Uppsala, Sweden). They were stimulated directly after isolation and examined for cell death by forward/side scatter analysis in FACScan after 48 h.
Isolation of PMBCs
Human peripheral mononuclear blood cells (PMBCs) were isolated from heparin-anticoagulated blood of healthy human donors by centrifugation with Ficoll-Paque PLUS (Amersham Pharmacia Biotech) and cultivated as described above for the Jurkat cells. Cells were stimulated immediately after isolation and examined for cell death in FACSCalibur by forward/side scatter analysis after 48 h.
Detection and quantification of apoptosis
Quantification of apoptosis was performed according to Nicoletti et al. 21 Briefly, cells were incubated over night in a hypotonic buffer (0.1% sodium citrate, 0.1% Triton X-100 and 50 mg/ml PI) and analyzed by flow cytometry on a FACSCalibur (Becton Dickinson, Heidelberg, Germany). Nuclei to the left of the G 1 peak containing hypodiploid DNA were considered apoptotic. For primary cells specific apoptosis was calculated as ((absolute apoptosis of compound-treated cellsÀabsolute apoptosis of untreated cells)/(100Fabsolute apoptosis of untreated cells) Â 100). Synergistic effects were determined by analysis of the fractional product. 22 Analysis of cytochrome c, Smac/DIABLO and Omi/HtrA2 release Release of mitochondrial proteins into cytosol was analyzed according to Leist et al. 23 Briefly, cells were collected by centrifugation and washed with phosphate-buffered saline (PBS). Cell pellets were resuspended in permeabilization buffer (210 mM D-mannitol, 70 mM sucrose, 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 5 mM succinate, 0.2 mM ethylene glycol tetraacetic acid, 0.15% bovine serum albumin, 60 mg/ml digitonin, pH 7.2, protease inhibitor Complete (Roche, Mannheim, Germany) and incubated for 20 min at 4 1C. Permeabilized cells were centrifuged (10 min, 170 g, 4 1C), the supernatant collected and centrifuged again (10 min, 13 000 g, 4 1C). The obtained cytosol was separated by SDS-polyacrylamide gel electrophoresis (PAGE). The remaining pellet of permeabilized cells was lyzed in 0.1% Triton/PBS (15 min, 4 1C), centrifuged (10 min, 13 000 g, 4 1C) and the supernatant containing mitochondrial proteins was analyzed by SDS-PAGE.
Western blot analysis
Cells were collected by centrifugation, washed with ice-cold PBS and lyzed in 1% Triton X-100, 0.15 M NaCl and 30 mM Tris-HCl, pH 7.5 with the protease inhibitor complete (Roche) for 30 min. Lysates were centrifuged at 10 000 g for 10 min at 4 1C. Equal amounts of protein were separated by SDS-PAGE and transferred to polyvinylidene difluoride membranes (Immobilon-P; Millipore, Eschborn, Germany). Membranes were blocked with 5% fat-free milk powder in PBS containing 0.05% Tween-20 ( TaqMan reverse-transcriptase-polymerase chain reaction RNA was isolated from Jurkat leukemia cells with the RNeasy Mini Kit (Qiagen, Hilden, Germany) following the manufacturer's protocol. RNA purity was confirmed by the 260/280 nm ratio and its integrity was established by agarose gels. Total RNA (2 mg) was reverse-transcribed using TaqMan Reverse Transcriptase Reagents (Applied Biosystems, Foster City, CA, USA). Experiments were performed employing the ABI 7300 RealTime PCR System (Applied Biosystems) using the TaqMan Universal PCR Master Mix Reagents Kit as recommended by the manufacturer. Ribosomal RNA (18S rRNA) was used as endogenous control. XIAP and 18 s rRNA primer and probes were purchased as predesigned TaqMan Gene Expression Assays by ABI (Applied Biosystems).
Colony-formation assay
Jurkat cells were left untreated or treated with spongistatin 1 or etoposide for 4 h. Subsequently, cells were washed with PBS and resuspended in culture medium (5 Â 10 5 cells per ml). Cell suspensions were diluted 1:10 with methylcellulose (0.52%) medium containing 40% FCS. Cells were seeded in 96-well plates (100 ml) and colonies were scored after 7 days of culture.
Statistical analysis
All experiments were performed at least three times in triplicate. Results are expressed as mean value±s.e. One-way analysis of variance (ANOVA) with Dunnett's post-test and Student's unpaired two-tailed t-test were performed using GraphPad Prism version 3.00 for Windows (GraphPad Software, San Diego, CA, USA). P-values of o0.05 were considered significant. 
Spongistatin 1 induces cell death in primary leukemic cells and wild-type Jurkat leukemia T cells
To assess the potential of spongistatin 1 for the treatment of acute leukemia, we tested the effects of the substance on primary tumor cells obtained from children suffering from acute leukemia. As shown in Figure 1a , spongistatin 1 at a low nanomolar concentration induced cell death (more than 10% specific apoptosis) in 11/12 (91.7 %) samples tested and was more effective in vitro than 8/10 (80%) conventional cytotoxic drugs tested in parallel using peak plasma, mostly micromolar concentrations ( Figure 1b) . Most importantly, spongistatin shows a minor toxicity on healthy human PMBCs ( Figure 1a , right panel) pointing to a rather selective effect on tumor cells. Due to this extraordinary potency we were interested in the underlying signaling mechanism. Therefore apoptosis induction by spongistatin 1 was investigated in wild-type Jurkat leukemia T cells. Apoptosis occurred in a dose-and time-dependent manner. The onset of apoptosis was significant 16 h after exposure to spongistatin 1 (200 pM, Figure 2a ) and at a concentration as low as 100 pM (24 h; Figure 2b ). More importantly, spongistatin 1 also displays long-term effects on leukemic cells as shown by clonogenic assay. After stimulation with spongistatin 1 for just 4 h, Jurkat cells have a strongly reduced ability to form colonies, indicating chemotherapeutical potential (Figure 2c ).
Spongistatin 1-induced apoptosis is dependent on caspase activation
The contribution of caspases in spongistatin 1-induced cell death has been examined by use of the broad-range caspase inhibitor zVAD-fmk (benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone). Caspase inhibition led to an almost complete suppression of spongistatin 1-induced DNA fragmentation (Figure 3a) , proving the importance of caspases in this apoptotic process. The activation of the respective initiator and effector caspases was elucidated by western blot analysis (Figure 3b ). The initiator caspases-8 and -9 as well as the 
Spongistatin 1 induces cell death by mitochondrial pathway-mediated caspase-9 activation
To elucidate the impact of either the extrinsic or intrinsic pathways, we used Jurkat cells deficient in caspase-8 (caspase-8 À/À ) 18 as well as Jurkat cells deficient in caspase-9 (caspase-9 À/À ). 19 In caspase-8 À/À cells, no reduction of apoptosis could be detected compared to control cells (Figure 4a ). Apoptosis was also not inhibited in the subclone R-Jurkat cells, which lack the CD95 receptor 15 ( Figure 4b ) and in FADDdeficient Jurkat cells 16 (Figure 4a) , further supporting the idea that spongistatin 1 acts independent of the classical deathreceptor pathway.
By contrast, caspase-9 deficiency almost completely inhibited spongistatin-induced DNA fragmentation (Figure 4c ) and abrogated the activation of the effector caspases-2 and -3 (data not shown), pointing to a pivotal role of the mitochondriamediated cell death signaling. 
Spongistatin 1-induced apoptosis L Schyschka et al
The antiapoptotic Bcl-2 family proteins Bcl-xL and Bcl-2 are important in inhibiting mitochondria-dependent intrinsic cell death pathways. Figure 5b shows that Bcl-xL as well as Bcl-2-overexpressing Jurkat cells were protected against spongistatin 1 compared to control cells. This further emphasizes the idea that spongistatin 1 induces a mitochondria-dependent pathway of apoptosis.
Spongistatin 1 induces protein degradation of X-linked inhibitor of apoptosis and is able to kill XIAP-overexpressing cells
Spongistatin-induced apoptosis is driven by activated caspases. XIAP is the most potent natural cellular inhibitor of active caspases and XIAP overexpression is discussed to be responsible for apoptosis resistance of certain tumor cells. Interestingly, spongistatin 1 is able to overcome overexpression of XIAP. XIAP-overexpressing cells (X-Jurkat) treated with various concentrations (100, 200 and 500 pM) of spongistatin 1 for different time points (8, 16 
Spongistatin 1 synergistically enhances staurosporine-induced cell death
We studied, whether spongistatin 1 might enhance the cell death induced by another apoptosis-inducing agent such as staurosporine. We treated wild-type Jurkat cells with low concentrations of spongistatin 1, staurosporine and a combination of both and quantified apoptosis induction after 24 h. As shown in Figure 7a , the combination of both agents significantly enhances apoptosis. To estimate the role of XIAP degradation for the above shown synergistic effect, the chemosensitizing activity was analyzed in XIAP-overexpressing Jurkat cells. Indeed, combination of spongistatin and staurosporine synergistically multiplies apoptosis (Figure 7a ). This cooperative effect was even stronger than in wild-type cells, indicating that spongistatin is able to sensitize cells toward apoptosis in XIAP-overexpressing tumor cells. In terms of therapeutical application we investigated the effect of the combination of both drugs on healthy PMBCs. Importantly, spongistatin does not corroborate the toxic effect of staurosporine on PMBCs and does not induce apoptosis itself at a concentration of 50 pM (Figure 7a , right panel). Interestingly, spongistatin at this concentration already is able to degrade XIAP (Figure 7b ). The combination with staurosporine leads to a significant degradation of XIAP in XIAP-overexpressing cells, being in line with increased apoptosis levels in X-Jurkat cells after treatment with the combination of these two substances.
Discussion
This work identifies spongistatin 1, a marine natural product, as a powerful antileukemic compound. Apoptosis is already induced in a picomolar range in Jurkat cells. Most importantly, spongistatin is also active in patient leukemic cells, where low concentrations of spongistatin 1 induce apoptosis more effectively than 8/10 clinically applied cytotoxic drugs used in peak plasma concentration that mostly covers micromolar ranges. Moreover, spongistatin only slightly affects healthy blood cells, making it an attractive new chemotherapeutic agent. Although no data are available yet on toxicity and plasma levels of spongistatin 1 in vivo, these data suggest that spongistatin 1 might represent a highly active new compound for apoptosis induction in leukemia tumor cells. Moreover spongistatin 1 treatment also potently abrogates long-term survival of leukemic cells.
This study provides clear experimental evidence that spongistatin 1 triggers apoptosis by the release of mitochondrial À/À cells (c) were treated with the indicated concentrations of spongistatin 1 for 24 h. Apoptotic cells were quantified by flow cytometry as described under Materials and methods. All experiments were carried out three times in triplicate. Data points, the mean ± s.e. of three independent experiments. Spongistatin 1-induced apoptosis L Schyschka et al factors such as cytochrome c, Smac or Omi/HtrA2 and subsequently the activation of caspases. Two initiator caspases, caspases-8 and -9 are activated by spongistatin, however only caspase-9 is requested for the apoptotic DNA fragmentation. This fact together with the data that Bcl 2 or Bclx L overexpression clearly rescues cells from spongistatin-induced death strongly argues for involvement of the intrinsic pathway. Apoptotic cell death was furthermore clearly dependent on caspase activation by spongistatin 1 as shown by the use of the broad-spectrum caspase inhibitor zVAD-fmk.
At a fundamental level, cancer occurs or progresses because malignant cells fail to undergo apoptosis either spontaneously or in response to chemotherapy. The principal mediators of apoptosis are caspases and failure to activate caspases account for resistance to apoptosis. 24 The activity of caspases is countered by certain IAPs. To this resue, X chromosome-linked inhibitor of apoptosis (XIAP), the best studied member of the IAP family, is differentially upregulated in many forms of human cancer suggesting its potential as an anticancer target. 25, 26 To prevent cell death XIAP directly binds to and inhibits the upstream initiator caspase-9 by its BIR3 region, and the downstream effector caspases-3 and -7 by the BIR2 domain. 27, 28 Thus IAPs including XIAP define a distal checkpoint for cell death control downstream of many proteins of relevance to tumor biology such as p53 or Bcl2 proteins and at a distal step in apoptosis pathways, at the convergence of intrinsic mitochondrial-dependent and by mitochondrial-independent extrinsic death pathways. Potentially bypassing many upstream defects in apoptosis-regulatory mechanisms in tumors XIAP inhibition or antagonism is an attractive strategy for restoring apoptosis sensitivity in refractory cancers. 29 Our data introduce spongistatin 1 as a highly promising experimental drug in this context. Spongistatin, in contrast to other chemotherapeutics such as etoposide, is able to Because spongistatin 1 had no effect on XIAP mRNA level, the reduced XIAP protein level is most likely the result of enhanced post-transcriptional degradation by a so far unidentified mechanism. To this end a variety of mechanism responsible for XIAP degradation has been described such as proteasome-mediated degradation, 30 cleavage by caspases 31 or calpains. 32 However, the most important feature in terms of a therapeutically benefit of this new experimental drug is the sensitization of leukemic cells for other chemotherapeutics. Interestingly the extent of this cooperative effect of spongistatin on low-dose treatment with staurosporine was much more pronounced in XIAP-overexpressing cells than in wild-type Jurkat cells. This fact together with the lack of sensitization in healthy blood cells underlines the importance of XIAP targeting by spongistatin in the sensitization of leukemic cells for apoptotic death. However regarding the attractivity of XIAP as a drug target overcoming chemoresistance it is of note that XIAP regulates apoptosis in a context-dependent manner: XIAP inhibition has been shown to fail to sensitize leukemia cells treated with etoposide 20 or in breast carcinoma cells upon treatment with carboplatin or doxorubicin. 33 Along this line spongistatin 1 also showed only a cooperative effect on leukemic cells death when cells were treated with low-dose staurosporine but not with etoposide (data not shown). Thus the vulnerability of tumors cells to XIAP inhibition seems to be dependent on the apoptotic stimuli applied and has to be evaluated.
Still, approaches antagonizing XIAP have not lost their attractivity in search of potent antitumor strategies. XIAP antisense oligonucleotides as well as ectotopic expression of Smac, an endogeneous inhibitor of IAPs provided the proof of principle by enhancing efficacy of chemo-and/or radiotherapy of cancer. [34] [35] [36] [37] [38] Consequently a variety of small molecule inhibitors of XIAP have been developed such as polyphenylurea derivatives, the natural compound embellin and others 29, 39 and shown to directly induce apoptosis of tumor cell lines in vitro and sensitize cancer cells to chemotherapeutic drugs.
Besides the valuable chemosensitizing profile of spongistatin 1, this compound induces apoptosis in 11/12 primary tumor cells of children suffering acute leukemia. Since no in vivo data are known for spongistatin 1 so far, the maximal tolerable plasma concentration of spongistatin 1 remains elusive. When used in low nanomolar concentrations, spongistatin induces apoptosis more efficiently than 8/10 clinically applied conventional cytotoxic drugs used in micromolar concentrations. As 300-100 000 times higher concentrations are needed of clinically applied cytotoxic drugs for induction of apoptosis compared to spongistatin 1, spongistatin 1 might represent an interesting new compound within the intensive search of new cytotoxic drugs for the treatment of leukemia. In this respect, it is important to know that high level of XIAP correlate with poor survival in childhood de novo acute myeloid leukemia. 40 In conclusion, the natural marine compound, spongistatin 1, potently induces apoptosis in patient leukemic cells and inhibits long-term survival of leukemic T cells, whereas toxicity on normal blood cells is low. It also kills XIAP-overexpressing, apoptosis-resistant, leukemic cells and inhibits their clonogenic survival. Spongistatin degrades XIAP protein in leukemic cells, which might be the reason for its potentizing effect when combined with other caspase-activating anticancer drugs. Spongistatin 1 thus might prove beneficial to face the problems in treating leukemia. 
